← Back to patent-cliff list
CAS 192569-17-8
(10R,11R,13S,17R)-11-hydroxy-10,13-dimethyl-1,3',4',8,9,10,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H)-dione
Codes: EPLE-001
Application context (from source-drug indications)
HypertensionEplerenoneHeart failureEplerenone醛固酮增多症EplerenoneMyocardial infarctionEplerenoneChronic renal impairmentEplerenoneEssential hypertensionEplerenone
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Eplerenone | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(10R,11R,13S,17R)-11-hydroxy-10,13-dimethyl-1,3',4',8,9,10,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H)-dione→2-hydroxy-2-methylpropanenitrile→(2R,5'R,7'R,10'R,11'R,13'S)-18'-amino-11'-hydroxy-10',13'-dimethyl-3',5-dioxo-1',2',3',4,5,6',7',8',9',10',11',12',13',14',15',16'-hexadecahydro-3H,5'H-spiro[furan-2,17'-[4,7](metheno)cyclopenta[a]phenanthrene]-5'-carbonitrile→(2R,5'S,7'R,10'R,11'R,13'S)-11'-hydroxy-10',13'-dimethyl-3',5,18'-trioxohexadecahydro-3H-spiro[furan-2,17'-[4,7]methanocyclopenta[a]phenanthrene]-5'(2'H)-carbonitrile→methyl (7R,10R,11R,13S,17R)-11-hydroxy-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate→methyl (7R,10R,11R,13S,17R)-10,13-dimethyl-11-((methylsulfonyl)oxy)-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate→methyl (7R,10S,13S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,10,12,13,14,15,16-tetradecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate
(10R,11R,13S,17R)-11-hydroxy-10,13-dimethyl-1,3',4',8,9,10,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H)-dione→(10R,13S,17R)-10,13-dimethyl-1,3',4',8,10,12,13,14,15,16-decahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H)-dione→(1'R,2R,3a'R,7a'R,9a'S,12a'S,12b'R)-7a',9a'-dimethyl-1',3,4,6',7',7a',9',9a',11',12',12a',12b'-dodecahydro-2'H,5H-spiro[furan-2,10'-[1,3a]methanobenzo[b]indeno[5,4-d]oxepine]-2',5,5'(4'H)-trione→(10R,11R,13S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',8,9,10,11,12,13,14,15,16-tetradecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-11-yl methanesulfonate→(1'R,2R,3a'R,7a'R,9a'S)-7a',9a'-dimethyl-1',3,4,6',7',7a',9',9a',11',12',12a',12b'-dodecahydro-2'H,5H-spiro[furan-2,10'-[1,3a]methanobenzo[b]indeno[5,4-d]oxepine]-5,5'(4'H)-dione→3-methyl-3-(trifluoromethyl)dioxirane→(1'R,2R,2'S,3a'R,7a'R,9a'S)-2'-hydroxy-7a',9a'-dimethyl-1',3,4,6',7',7a',9',9a',11',12',12a',12b'-dodecahydro-2'H,5H-spiro[furan-2,10'-[1,3a]methanobenzo[b]indeno[5,4-d]oxepine]-5,5'(4'H)-dione
(10R,11R,13S,17R)-11-hydroxy-10,13-dimethyl-1,3',4',8,9,10,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H)-dione→methyl (7R,10R,11R,13S,17R)-11-hydroxy-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate→methyl (7R,10R,11R,13S,17R)-10,13-dimethyl-11-((methylsulfonyl)oxy)-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate→methyl (7R,10S,13S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,10,12,13,14,15,16-tetradecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylate→(7R,8R,9S,10R,11R,13S,14S,17R)-11-hydroxy-10,13-dimethyl-7-(nitromethyl)-1,3',4',6,7,8,9,10,11,12,13,14,15,16-tetradecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H)-dione→(7R,8S,9S,10R,11R,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-carboxylic acid
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.